Comparative evaluation of ketoconazole-β-cyclodextrin systems prepared by coprecipitation and kneading
dc.Affiliation | October University for modern sciences and Arts (MSA) | |
dc.contributor.author | A. Marzouk, Maha | |
dc.contributor.author | A. Kassem, Alaa | |
dc.contributor.author | M. Samy, Ahmed | |
dc.contributor.author | I. Amer, Reham | |
dc.date.accessioned | 2020-01-30T09:43:40Z | |
dc.date.available | 2020-01-30T09:43:40Z | |
dc.date.issued | 2010 | |
dc.description | MSA Google Scholar | en_US |
dc.description.abstract | Ketoconazole (KZ), an imidazole antifungal, was formulated into inclusion complexes via coprecipitation and kneading with β-cyclodextrin (β-CD) as a carrier in 1:1 and 1:2 drug to carrier ratios. The KZ-β-CD solid complexes were characterized by X-ray diffraction and differential scanning calorimetry (DSC). The diffraction pattern of the pure drug revealed the drug to be highly crystalline in nature, as indicated by numerous distinctive peaks. The lack of numerous distinctive peaks of the drug in KZ-β-CD complexes prepared by the two methods revealed that a large number of the drug molecules were dissolved in a solid-state carrier matrix with an amorphous structure. The thermograms of the KZ-β-CD complexes showed a strong reduction in the intensity and broadening of drug peaks somewhat in both kneading and coprecipitation systems, suggesting that the drug is monomolecularly dispersed in the β-CD cavity. The prepared tablets of KZ-β-CD solid complexes prepared by the two methods were evaluated for their quality control testing, and an in vitro release study and the results of quality control complied with pharmacopeial requirements and the release profiles indicated complete drug release after 30 min. The kinetic parameters obtained from release data were analyzed in order to explain the mechanism of drug release and revealed non-Fickian transport. Accelerated stability testing at 35°C, 45°C, and 55° C and at 75% relative humidity was carried out for six months and revealed somewhat stable systems as indicated by a t90 of about 2 years for both KZ-β-CD systems. A microbiological in vitro assay of KZ from the prepared tablets was performed using Candida albicans as a model fungus, and KZ had improved microbiological activity when administered as an inclusion complex with β-CD. The results confirmed the benefit of using CDs as a useful tool to enhance the dissolution and hence bioavailability of poorly water-soluble drugs by forming solubilizing systems when exposed to gastrointestinal fluid. | en_US |
dc.description.sponsorship | Drug Discoveries & Therapeutics | en_US |
dc.identifier.citation | 1. Remon JP, Belparie F, Van Severen R, Braeckman P. Interaction of antacids with antiarrhythmics. V. Effect of aluminium hydroxide and magnesium oxide on the bioavailability of quinidine, procainamide and propranolol in dogs. Arzneim Forsch. 1983; 33:117-120. 2. Wang L, Tang X. A novel ketoconazole bioadhesive effervescent tablet for vaginal delivery: Design, in-vitro and 'in-vivo' evaluation. Int J pharm. 2008; 350:181-187. 3. USP XXV. The United States Pharmacopoeia, NF 20, US. Pharmacopieal Convention, Inc., Rockville, MD, USA, 2002; p. 1148. 386 Method of preparation Coprecipitated KZ-β-CD Kneaded KZ-β-CD K35 (days) –1 0.017 0.018 K45 (days) –1 0.020 0.022 K55 (days) –1 0.024 0.025 K20 (days) –1 0.01329 0.01326 t90 (year) 2.06 2.07 t1/2 (year) 10.30 10.32 Table 5. Kinetic parameters for accelerated stability testing of KZ tablets Ea (Cal/mol) 3,072.126 3,857.295 Figure 6. Inhibition zones of kneaded KZ-β-CD 1:2. (A) 1.8 μg/μL; (B) 3.6 μg/μL; and (C) 5.4 μg/μL. Figure 5. Histogram of the mean values of the inhibition zones diameters of KZ tablets, a commercial product, and a reference solution at different concentrations. Open column, 1.8 μg/μL of KZ; Closed column, 3.6 μg/μL of KZ; Gray column, 5.4 μg/μL of KZ. Coppt. and Knead. represent coprecipitated and kneaded, respectively. www.ddtjournal.com Drug Discoveries & Therapeutics. 2010; 4(5):380-387. 4. Carlson JA, Mann HJ, Canafax DM. Effect of pH on disintegration and dissolution of ketoconazole tablets. Am J Hosp Pharm. 1983; 40:1334-1336. 5. Esclusa-Diaz MT, Guimaraens-Méndez M, Pérez-Marcos MB, Vila-Jato JL, Torres-Labandeira JJ. Characterization and in vitro dissolution behaviour of ketoconazole/β- and 2-hydroxypropyl-β-cyclodextrin inclusion compounds. Int J Pharm. 1996; 143:203-210. 6. Heo MY, Piao ZZ, Kim TW, Cao QR, Kim A, Lee BJ. Effect of solubilizing and microemulsifying excipients in polyethylene glycol 6000 solid dispersion on enhanced dissolution and bioavailability of ketoconazole. Arch Pharm Res. 2005; 28:604-611. 7. Jambhekar S, Casella R, Maher T. The physicochemical characterization and bioavailability of indomethacin from β-cyclodextrin, hydroxylethyl-β-cyclodextrin, and hydroxypropyl-β-cyclodextrin complexes. Int J Pharm. 2004; 270:149-166. 8. Nagarsenker MS, Joshi MS. Celecoxib-cyclodextrin systems: Characterization and evaluation of in vitro and in vivo advantage. Drug Dev Ind Pharm. 2005; 31:169-178. 9. Choi HG, Lee BJ, Han JH, Lee MK, Park KM, Yong CS, Rhee JD, Kim YB, Kim CK. Terfenadine-β-cyclodextrin inclusion complex with antihistaminic activity enhancement. Drug Dev Ind Pharm. 2001; 27:857-862. 10. Svehla G. In: Vogel's Qualitative Inorganic Analysis. 7th ed., Thomson Press India Ltd., Mumbai, India, 1996; p. 207. 11. Lindahl A, Ungell AL, Kunston L, Lennernäs H. Characterization of fluids from stomach and proximal jejunum in men and women. Pharm Res. 1997; 387 14:497-502. 12. Karasulu HY, Hilmioğlu S, Metin DY, Güneri T. Efficacy of a new ketoconazole bioadhesive vaginal tablet on Candida albicans. Farmaco. 2004; 59:163-167. 13. Ritger PL, Peppas NA. A simple equation for description of solute release. II. Fickian and anomalous release from swellable device. J Control Release. 1987; 5:37-42. 14. Vaucher LC, Breier AR, Schapoval EE. Microbiological assay for the determination of telithromycin in tablets. J AOAC Int. 2006; 89:1398-1402. 15. Vanitha J, Saravana Kumar A, Ganesh M, Saravanan VS. Comparative analysis of climbazole in pharmaceutical formulation. Asian J Research Chem. 2008; 1:43-45. 16. Bergamasco Rde C, Zanin GM, de Moraes FF. Sulfluramid volatility reduction by beta-cyclodextrin. J Agric Food Chem. 2005; 53:1139-1143. 17. Tayade PT, Vavia PR. Inclusion complexes of ketoprofen with β-cyclodextrins: Oral pharmacokinetics of ketoprofen in human. Indian J Pharm Sci. 2006; 68:164-170. 18. Abdelkader H, Abdallah OY, Salem HS. Comparison of the effect of tromethamine and polyvinylpyrrolidone on dissolution properties and analgesic effect of nimesulide. AAPS PharmSciTech. 2007; 8:E65. 19. Choi HG, Kim DD, Jun HW, Yoo BK, Yong CS. Improvement of dissolution and bioavailability of nitrendipine by inclusion in hydroxypropyl-β-cyclodextrin. Drug Dev Ind Pharm. 2003; 29:1085-1094. | en_US |
dc.identifier.doi | https://doi.org/ | |
dc.identifier.other | https://doi.org/ | |
dc.identifier.uri | https://t.ly/1Mb1A | |
dc.language.iso | en | en_US |
dc.publisher | Drug Discoveries & Therapeutics | en_US |
dc.relation.ispartofseries | Drug Discov. Ther;Volume: 4 Pages: 380-387 | |
dc.subject | University of Ketoconazole, β-cyclodextrin inclusion complex, spectroscopic study, tablets, quality control, in vitro release, stability, microbiological study | en_US |
dc.title | Comparative evaluation of ketoconazole-β-cyclodextrin systems prepared by coprecipitation and kneading | en_US |
dc.type | Article | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 51 B
- Format:
- Item-specific license agreed upon to submission
- Description: